Vaccines
19 November 2024
Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine15 November 2024
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease15 November 2024
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V215 November 2024
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX83613 November 2024
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis12 November 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial11 November 2024
Theragent and CellVax Therapeutics Announce First Patient Dosed in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy29 October 2024
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY25 October 2024
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine23 October 2024
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease17 October 2024
Longhorn Vaccines and Diagnostics Highlights New Data for LHNVD-303 its Bacterial Sepsis Vaccine at IDWeek 202415 October 2024
Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease10 October 2024
Novavax’s Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU7 October 2024
Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue2 October 2024
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-140323 September 2024
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine20 September 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European UnionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports